Co-Targeting of MDM2 and CDK4/6 with Siremadlin and Ribociclib for the Treatment of Patients with Well-Differentiated or Dedifferentiated Liposarcoma: Results from a Proof-of-Concept, Phase Ib Study.
Albiruni R Abdul RazakSebastian BauerCristina SuarezChia-Chi LinRichard QuekMarie Luise Hütter-KrönkeRicardo CubedoStephane FerrettiNelson GuerreiroAstrid JullionElena J OrlandoGiorgia ClementiJanna Sand DejmekEnsar HalilovicClaire FabreJean Yves BlayAntoine ItalianoPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2022)
Siremadlin plus ribociclib demonstrated manageable toxicity and early signs of antitumor activity in patients with advanced WDLPS or DDLPS.